Uromigos Live 2024: Focus on Prostate Cancer
Advertisement
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
The first part of five segments from the Uromigos Live 2024 session on radioligands.
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
Listen to the podcast format of the panel on radioligand data in prostate cancer from Uromigos Live 2024.
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Listen to the podcast format of the panel on T cell directed therapy in prostate cancer from Uromigos Live 2024.
Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.